Viral capsid assembly intermediates and methods of production

a technology of viral capsids and intermediates, which is applied in the field of viral capsid production, can solve the problems of unanswered capsid assembly questions, difficult to administer, and low efficiency of hcv treatment, and achieve the effect of rapid diagnosis of viral infection

Inactive Publication Date: 2009-12-29
UNIV OF WASHINGTON
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0042]The subject invention offers several advantages over existing technology. A major advantage of the cell-free system is that it is amenable to a wide variety of manipulations. For example, since the only radiolabeled protein used generally is the capsid protein, it is an ideal system to use for pulse-chase analysis, in which a cohort of protein is followed over time. Furthermore, the reactions can be separated out into a protein synthesis phase and an assembly phase, and manipulations can be performed to address energy requirements during the assembly phase, independent of the synthesis phase. Other manipulations that can be performed, include reducing the concentration of transcript, removing RNA using RNAse A after protein synthesis is completed but while assembly is just starting, solubilizing membranes using detergent at the start of translation, and selectively removing specific factors from the extract before programming the reaction. This ability to manipulate the reaction allows testing of hypotheses concerning the mechanism of capsid assembly. In cellular systems, viral capsid assembly occurs too rapidly and efficiently to be easily dissected biochemically, but an advantage offered by the cell-free system is that once the mechanisms involved have been defined using the cell-free system, approaches can be devised to demonstrate the existence of these mechanisms in cellular systems. An example of this approach is the energy requirement of retrovirus capsid assembly, which was initially defined for HIV-1 in the cell free system, and subsequently was confirmed for M-PMV in cells (Welson, et al., (1998) J Virol 72, 3098-106.) Thus, cell-free systems have the unique ability to foster advances in understanding of biochemical mechanisms underlying complex cellular events, thereby stimulating new experimental approaches in other systems.

Problems solved by technology

In addition AZT has many adverse side effects, which in combination with its inability to reduce viral load provide for a very ineffective treatment option for HIV infected patients and many cannot tolerate it.
Available treatments for HCV, such as interferon, are costly, difficult to administer, and minimally effective (Lin and Keeffe Annu Rev Med 52, 29-49 ((2001)).
Despite recent breakthroughs in cellular systems for studying HCV replication, culture systems that release high titers of infectious virus do not currently exist.
The mechanisms involved in coordinating the formation of an viral capsids are not well elucidated and, many important questions about capsid assembly remain unanswered, including whether assembly generally is an energy-dependent process, whether host proteins are required for assembly to take place, and whether assembly proceeds by way of discrete intermediates.
A major obstacle to addressing these questions experimentally has been the inherent difficulty of studying capsid assembly in cellular systems.
Many of the events in question proceed extremely rapidly and are not readily amenable to manipulation, making it difficult to identify trans-acting factors and energy substrates that may be required for assembly.
There is a need for compounds for treatment of virally infected individuals that specifically inhibit viral replication, but do not have significant side effects and do not promote new strains of virus that are resistant to treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cell Free Protein Synthesis

[0091]1. Transcription

[0092]The plasmid containing the Gag coding region was linearized at the EcoRl site (as described in the NEB catalogue). The linearized plasmid was purified by phenol-chloroform extraction (as described in Sambrook, J., et al., in Molecular Cloning. A Laboratory Manual) and this plasmid was adjusted to a DNA concentration of 2.0 mg / ml. Transcription was carried out using a reaction that contained: 40 mM Tris Ac (7.5), 6 mM Mg Ac, 2 mM Spermidine, 0.5 mM ATP, 0.5 mM CTP, 0.5 mM UTP, 0.1 mM GTP, 0.5 mM diguanosine triphosphate (cap), 10 mM Dithiothreitol, 0.2 mg / ml transfer RNA (Sigma Chemical Co.), 0.8 units / microliter RNAse inhibitor (Promega), 0.4 units per microliter of SP6 Polymerase (NEB). Mutant DNAs were prepared as described by Gottlinger, H. G., et al., Proc. Natl. Acad. Sci. 86:5781-5785 (1989); Jowett, J. B. M., et al., J. Gen. Virol. 73:3079-3086 (1992); Hockley, D. J. et al., J. Gen. Virol. 75:2985-2997 (1994); or Zhao, Y....

example 2

Preparation of HSS, HSP, and HSPd

[0103]Where indicated, wheat germ extract prepared as described in Example 1 was centrifuged at either 50,000 rpm for 21 min or 100,000 rpm for 30 min in a TLA 100 rotor (Beckman Instruments, Palo Alto, Calif.). The supernatant (high-speed supernatant, HSS) of the 50,000 rpm spin was used for cell-free translation and assembly reactions. The pellet of the 100,000 rpm spin (high speed pellet, HSP) was resuspended at a 5× concentration in buffer (25 mM Hepes pH 7.4, 4 mM MgAc, 100 mM KAc, 0.25M sucrose). Wheat germ extract adjusted to contain a concentration 0.5% “NIKKOL” was subjected to the same ultracentrifugation in parallel to generate the detergent treated high-speed pellet (HSPd). This pellet was washed twice with 200 RL of the above non-detergent buffer in order to remove traces of detergent, and then resuspended as described above. Following treatment with emetine at 50 mm, 1.8 μL of HSP or HSPd was added to the 18 mL cell-free reactions progr...

example 3

Translation of Gag Pr55 Protein in a Cell Free System

[0104]The cell-free translation / assembly system of the invention contains the components described in Part A, above. Example 1 provides details of an exemplary system derived from wheatgerm extract, which is capable of supporting translation and assembly of HIV capsids. Briefly, protein synthesis was initiated in the cell-free translation / assembly system by adding an mRNA that encodes Gag Pr55 protein. Alternatively, when the system includes transcription means, such as SP6 or T7 polymerase, the reaction may be initiated by addition of DNA encoding the protein. Complete synthesis of protein and assembly into capsids is usually achieved within about 150 minutes. FIG. 2 shows that capsids formed in the cell-free system of the invention are substantially the same as those formed in cells. Shown in the Figure is a comparison of migration of the capsids through an isopycnic CsCl gradient, where capsids formed in the cell-free translati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A cell-free method for translation and assembly of viral capsid and capsid intermediates is disclosed. Also disclosed are novel capsid assembly intermediates and novel host proteins which bind to such assembly intermediates. The invention also includes a screening method for compounds that alter viral capsid assembly, and a method of treating viral infection using compounds which inhibit the capsid assembly pathway.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application in a continuation in part of U.S. Ser. No. 10 / 040,206 filed Jan. 2, 2002 now abandoned, which is a continuation in part of U.S. Ser. No. 09 / 020,144, filed Feb. 6, 1998 (issued on Jul. 15, 2003 as U.S. Pat. No. 6,593,103), which claims benefit of U.S. Ser. No. 60 / 039,309 filed Feb. 7, 1997 (expired on Feb. 7, 1998), which disclosures are hereby incorporated by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]This invention was made with Government support by Grant Nos. K08AI01292 and A141881, awarded by the National Institutes of Health (NIH) and National Institutes of Health AIDS Division, respectively. The Government has certain rights in this invention.INTRODUCTION[0003]1. Field of the Invention[0004]The invention is concerned with a method for producing viral capsids in a cell-free extract. Also described are capsid intermediate compositions, auxiliary proteins, and screening assays for drugs to inhibit ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): C12Q1/00C12P21/06C12Q1/68G01N33/53C12N15/09A61K45/00A61P31/12C07K14/00C07K14/005C07K14/02C07K14/16C07K14/18C07K14/47C07K16/08C12N5/02C12N5/08C12N7/00C12N7/01C12N7/04C12P21/00C12P21/02C12P21/08C12Q1/02
CPCC07K14/005C12N7/00C12P21/02C12N2730/10122C12N2740/16122C12N2770/24222C12N2730/10161A61P31/12
Inventor LINGAPPA, JAISRI R.KLEIN, KEVIN C.LINGAPPA, VISHWANATH R.
Owner UNIV OF WASHINGTON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products